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Abstract
Background: MicroRNAs (MiRNAs) are short non-coding RNAs that control protein expression
through various mechanisms. Their altered expression has been shown to be associated with
various cancers. The aim of this study was to profile miRNA expression in colorectal cancer (CRC)
and to analyze the function of specific miRNAs in CRC cells. MirVana miRNA Bioarrays were used
to determine the miRNA expression profile in eight CRC cell line models, 45 human CRC samples
of different stages, and four matched normal colon tissue samples. SW620 CRC cells were stably
transduced with miR-143 or miR-145 expression vectors and analyzed in vitro for cell proliferation,
cell differentiation and anchorage-independent growth. Signalling pathways associated with
differentially expressed miRNAs were identified using a gene set enrichment analysis.
Results:  The expression analysis of clinical CRC samples identified 37 miRNAs that were
differentially expressed between CRC and normal tissue. Furthermore, several of these miRNAs
were associated with CRC tumor progression including loss of miR-133a and gain of miR-224. We
identified 11 common miRNAs that were differentially expressed between normal colon and CRC
in both the cell line models and clinical samples. In vitro functional studies indicated that miR-143
and miR-145 appear to function in opposing manners to either inhibit or augment cell proliferation
in a metastatic CRC model. The pathways targeted by miR-143 and miR-145 showed no significant
overlap. Furthermore, gene expression analysis of metastatic versus non-metastatic isogenic cell
lines indicated that miR-145 targets involved in cell cycle and neuregulin pathways were significantly
down-regulated in the metastatic context.
Conclusion: MiRNAs showing altered expression at different stages of CRC could be targets for
CRC therapies and be further developed as potential diagnostic and prognostic analytes. The
identified biological processes and signalling pathways collectively targeted by co-expressed
miRNAs in CRC provide a basis for understanding the functional role of miRNAs in cancer.
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Background
Colorectal cancer (CRC) is one of the most frequent can-
cers and a common cause of cancer-related deaths in the
developed world [1]. The overall incidence of CRC is 5%
in the general population and the 5-year survival rate
ranges from 40% to 60% [2]. Prognosis largely relies upon
descriptive staging systems using morphology and his-
topathology of the tumor [3]. However, even morpholog-
ically similar tumors can differ in their underlying
molecular changes and tumorigenic potential. The devel-
opment of CRC from normal epithelial cells to malignant
carcinomas involves a multi-step process with accumula-
tion of both genetic and epigenetic changes, leading to a
temporal activation of oncogenes and inactivation of
tumor suppressor genes that confer a selective advantage
to cells containing these alterations [4]. Although most
sporadic CRC cases include changes in the WNT, KRAS,
TGFβ, β-catenin and p53 pathways, there appears to be
added complexity with additional signaling pathways
showing accumulated mutations [5,6]. This suggests that
alternative factors contribute to CRC and that underlying
levels of regulation exist to control the complex cross-talk
between different signal transduction pathways.
A number of CRC expression profiling studies on protein
coding genes have been performed to better resolve the
underlying molecular pathways and to further dissect the
different stages of CRC [7,8]. More recently, a newly dis-
covered class of short 22 nucleotide (nt) non-coding
RNAs, called microRNAs (miRNAs), have been identified
and implicated in cancer initiation and progression [9].
The biogenesis of these small RNAs involves transcription
by RNA polymerase II and processing of the primary tran-
script by the endonuclease Drosha to produce 60-70-nt
precursor miRNAs (pre-miRNAs) with imperfect hairpin
structures [10,11]. The pre-miRNA is transported into the
cytoplasm through exportin 5 [12,13] where it undergoes
processing by the RNAse III enzyme Dicer to produce
mature miRNAs that are then incorporated into a multi-
protein complex [14,15]. These miRNA-containing com-
plexes have been shown to bind to the 3' untranslated
region of multiple mRNAs through complementarity
between the resident miRNA strand and the target
sequence and, based on the degree of homology, direct
either translational inhibition or mRNA degradation [16].
To date, there have been 678 human miRNAs identified
(miRBase Sequence Database - Release 11) and, through
computational models, it has been suggested that there
may be greater than 1000 miRNA genes, comprising
approximately 3% of the currently known genes in the
human genome [17,18]. Moreover, bioinformatic analy-
ses estimate that miRNAs may regulate as many as 30% of
the human protein coding genes, suggesting that these
small RNAs may act to coordinate the interplay between
complex signal transduction pathways [19].
Many miRNAs have been identified as differentially
expressed between normal and tumor tissues or cancer
cell lines [20]. In CRC, there have been several studies
examining the expression patterns of miRNAs [21-27].
The first study showing de-regulation of miRNAs reported
the down-regulation of miR-143 and miR-145 as early as
the pre-adenomatous polyp stage, suggesting a possible
role for these miRNAs in early stages of CRC [24]. Subse-
quently, a group of 13 miRNAs showing differential
expression in CRC tumors was identified with the expres-
sion level of miR-31 being correlated with CRC tumor
stage [22]. Furthermore, a small number of clinical sam-
ples have been screened using a serial analysis of gene
expression approach to identify novel miRNAs [23]. Not-
withstanding these earlier studies in CRC, there still
remains the need to confirm earlier observations in a large
set of clinical CRC samples and examine the functional
consequences of altered miRNA expression in this cancer.
In this study, we profiled the expression of miRNAs in 45
clinical CRC samples, four matched normal colorectal tis-
sues and eight cell line models. We identified 11 miRNAs
commonly changed in expression levels between normal
colon and both clinical samples and cell lines. We demon-
strate that several miRNAs including miR-1 and miR-31
have evolving expression patterns between stages II and III
of CRC and may provide potential prognostic or diagnos-
tic markers for this cancer. Through functional studies, we
also show that re-expression of miR-143 or miR-145 leads
to tumor suppressor and oncogenic phenotypes in a met-
astatic CRC model, respectively. The observed oncogenic
effects of miR-145 were associated with the down-regula-
tion of the G1/S cell cycle checkpoint and neuregulin
pathways in the CRC metastatic setting compared to its
isogenically matched non-metastatic model. This path-
way analysis may explain the observed oncogenic effects
of miR-145 in metastatic CRC compared to its reported
tumor suppressor effects in the non-metastatic context.
Methods
Cell lines
SW620, SW480, HCT116 and HT29 cell lines were
obtained from the ATCC. KM20L2 and KM12C were pro-
vided by the NCI-Frederick Cancer DCT Tumor Reposi-
tory, while cell lines KM20 and KM12SM were supplied by
Dr Isaiah J. Fidler (The University of Texas MD Anderson
Cancer Center). SW620 and SW480 cells were grown in
Dulbecco's Modified Eagle Medium (D-MEM) (Gibco).
HCT116 cells were grown in McCoys 5A Media (Gibco)
and KM20, KM20L2, KM12C, KM12SM and HT29 cells
were grown in RPMI Media 1640 (Gibco). All media was
supplemented with 10% fetal bovine serum (JRH Bio-
sciences), 2 mM L-glutamine (Gibco) and Penicillin-
Streptomycin solution (0.1 U/mL penicillin and 0.1 μg/BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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mL streptomycin) (Gibco), except for the HT29 cells
which were cultured in 0.72 mM L-glutamine.
Clinical Samples
In total, 49 fresh-frozen human tissue samples were
obtained from Genomics Collaborative Inc. (Cambridge
MA) or Clinomics Bioscience, Inc (Pittsfield, MA), includ-
ing 4 normal colon, 4 Stage I, 19 Stage II, 20 Stage III and
2 Stage IV samples (Additional File 1). Fifteen of these
samples were profiled in replicate on the Ambion array. In
addition, we profiled four matched formalin fixed paraf-
fin embedded (FFPE) samples (B8TMKAN5, NLKEIAE3,
S6TRKAX6, and ZIPBBA2E). The median tumor content
of all CRC samples was 70%, with no significant differ-
ence in tumor content between early stage (I and II) versus
late stage (III and IV) disease.
miRNA profiling
The mirVana Bioarray (Ambion, version 1) that contains
287 human miRNA probes was employed to identify
colorectal cancer miRNA signatures [28]. MiRNA was iso-
lated from 5 ug of total RNA from colorectal samples
using the mirVana isolation kit (Ambion) for snap-frozen
samples and the RecoverAll™ Total Nucleic Acid Isolation
Kit for FFPE samples (Ambion). All samples were then
fractionated by polyacrylamide gel electrophoresis (Flash-
Page Ambion) and small RNAs (< 40 nt) were recovered
by ethanol precipitation with linear acrylamide. Quantita-
tive RT-PCR (QPCR) of miR-16 was used to confirm
miRNA enrichment prior to miRNA array analysis.
The small RNAs from all samples were subject to poly(A)
polymerase reaction wherein amine modified uridines
were incorporated (Ambion). The tailed samples were
then fluorescently labeled using the amine-reactive Cy3 or
Cy5 (Invitrogen). One- or two-color hybridizations were
performed for the clinical CRC or cell line profiling exper-
iments, respectively. For 2-color experiments, cell line
miRNA was directly compared to normal colon RNA
(Ambion). The fluorescently labeled RNAs were purified
using a glass-fiber filter and eluted (Ambion). Each sam-
ple was then hybridized to the Bioarray slides for 14 hours
at 42°C (Ambion). The arrays were then washed and
scanned using an Agilent 2505B confocol laser microarray
scanner (Agilent) and data was obtained using the Expres-
sion Analysis software (Codelink, version 4.2). The mir-
Vana microarray data have been deposited in the NCBI
GEO and are accessible through GEO series accession no.
GSE10259.
Statistical Analysis
The data were analyzed using the R software package. The
miRNA expression data were quantile normalized prior to
determining differential gene expression. Replicate sam-
ples and probe values were averaged and the Student t-test
was performed to find genes that vary significantly across
sample groups. Genes were selected if the median normal-
ized signal intensity was greater than 100 (75th percentile
of median signal) for at least one group, with a mean
change > 1.5-fold and a p-value < 0.05. A one-way
ANOVA was used to evaluate miRNA expression level
between normal and different cancer stages. Both probe
level and gene level data analysis was performed for all
group comparisons.
To compare miRNA profiles measured between matched
FFPE and fresh frozen tissue, or QPCR versus mirVana
array data, Taqman Ct values greater than 35 (approach-
ing background expression levels) were first removed and
then linear regression and Pearson correlation calcula-
tions were performed.
miRNA QPCR
QPCR was performed using the ABI early access miRNA
Taqman panel to verify miRNA expression profiles [29].
This included 169 individual assays as listed in Additional
File 2. Ten ng of total RNA was converted to cDNA using
the High Capacity DNA Archive kit and 3 ul of 5× RT
primer according to the manufacturer's instructions
(Ambion). The 15 μl reactions were incubated in a ther-
mocycler for 30 min at 16°C, 30 min at 42°C, 5 min at
85°C and held at 4°C. All reverse transcriptase reactions
included no template controls. QPCR was performed
using a standard Taqman® PCR kit protocol on an Applied
Biosystems 7900 HT Sequence Detection System. The 10
μl PCR reaction included 0.66 μl RT product, 1 μl Taqman
miRNA assay primer and probe mix, 5 μl Taqman 2× Uni-
versal PCR master mix (No Amperase UNG) and 3.34 μl
water. The reactions were incubated in a 384 well plate at
95°C for 10 mins, followed by 40 cycles of 95°C for 15
sec, and 60°C for 2 min. All QPCR reactions included a no
cDNA control and all reactions were performed in tripli-
cate.
Plasmid constructs
The plasmid pSilencer 2.1 (Ambion) was modified within
the multiple cloning site to introduce unique restriction
sites and a RNA polymerase III transcriptional terminator
(TTTTTT). The following oligonucleotides were synthe-
sized (Sigma), annealed and ligated to pSilencer 2.1, pre-
digested with BamHI and HindIII, to produced pSilencer
2.1 Term: pSilU6upper 5'GATCCCTCGAGTCTA-
GATTTTTTGGAAA and pSilU6lower 5'AGCTTTTC-
CAAAAAATCTAGACTCGAGG. The DNA encoding pre-
miR-143 was PCR-amplified from human genomic DNA
using primers 143F (5'CGGGATCCCGGAGAGGT-
GGAGCCCAGGTC) and 143R (5'GCTCTAGACAGCAT-
CACAAGTGGCTGA), digested with BamHI and XbaI and
ligated to pSilencer 2.1Term to produce the miR-143
expression plasmid. For miR-145, genomic DNA wasBMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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recovered as a PCR amplicon using primers 145F
(5'CGGGATCCCAGAGCAATAAGCCACATCC) and 145R
(5'GCTCTAGACTCTTACCTCCAGGGACAGC), digested
with BamHI and XbaI and ligated into pSilencer 4.1 under
control of the CMV promoter.
Generation of stable cell lines
To generate stable clones using pSilencer 2.1 (miR-143)
and pSilencer 4.1 (miR-145) plasmids, 1-5 × 106 SW620
cells were seeded in a single well of a 6-well plate. Upon
reaching 80-90% confluence cells were transfected with 4
ug plasmid DNA using Lipofectamine 2000 according to
the manufacturer's instructions. Cells were diluted and
plated in fresh medium containing 500 ug/ml hygromy-
cin. After 14 days of selection, independent clones were
picked, expanded and screened for expression of the spe-
cific miRNA(s) encoded by the transfected plasmid.
Antisense experiments
Biotinylated 2'-O-methyl antisense miR-145 RNA or con-
trols were delivered to SW620 using Lipofectamine 2000
(Invitrogen) as detailed in the Supplementary Methods.
Transfection efficiency was at least 80% in all experi-
ments. All experiments were performed in triplicate.
Cell proliferation assay
SW620 cells (3 × 103 cells/well) were seeded in 96-well
plates in serum-containing media. Cell viability analysis
was conducted on day 0 (day of seeding) and on day 5. A
total of 20 μL of Cell Titer-Blue reagent (Promega) was
added to each well and the plate incubated at 37°C for 2
hours. Fluorescence was measured using the FLUOstar
OPTIMA microplate reader (BMG Labtech). To conduct
serum-free analysis, the media was changed to serum-free
media on day 1.
Rapid soft agar assay
2× Iscove's Modified Dulbecco's Medium (IMDM)
(Gibco) was supplemented with 0.6% Sodium Bicarbo-
nate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-
glutamine (Gibco), 2× Non Essential Amino Acid Solu-
tion (Gibco), 2% Sodium Pyruvate (Gibco) and Penicil-
lin-Streptomycin solution (0.1 U/mL penicillin and 0.1
μg/mL streptomycin) (Gibco). 2× IMDM was mixed at a
ratio of 1:1 with 1.2% Bacto Agar (55°C) and 50 μL was
added per well to a 96-well plate to produce a pre-layer for
the assay. Ten μL of cell suspension containing SW620
cells (3 × 103), 20 μL of 2× IMDM and 30 μL 0.8% Bacto
agar (55°C) was mixed and transferred to the solidified
pre-layer in each well. The semi-solid feeder layer was pre-
pared by mixing 25 μL of 2× IMDM and 25 μL of 1.2%
Bacto Agar (55°C) and layered on top of the solidified cell
layer. The cells were left to grow in a CO2 incubator at
37°C for 7 days. Proliferation and cell viability were
scored using the Cell Titer-Blue reagent (Promega).
Live cell imaging
The Nikon Diaphot biological microscope and the Nikon
E995 digital camera were used to capture the cell mor-
phology images.
Antisense-mediated suppression of miR-145
A total of 100 nM of biotinylated 2'-O-methyl antisense
miR-145 RNA (5' AAG GGA UUC CUG GGA AAA CUG
GAC 3') (IDT) or the reverse control (5' CAG GUC AAA
AGG GUC CUU AGG GAA 3') (IDT) were transfected with
Lipofectamine 2000 (Invitrogen) into 2 × 106 SW620/
miR-145 cells. At 48 hours post-transfection, the cells
were harvested and total RNA extracted using TRIzol (Inv-
itrogen) according to the manufacturer's instructions. 100
ug of total RNA was subjected to three sequential deple-
tions using 250 ug of Dynabeads M-280 Streptavidin
coated magnetic beads (Invitrogen). Each depletion
involved washing the beads twice with 0.1 M NaOH, 0.05
M NaCl solution and then once with 0.1 M NaCl. The
beads were resuspended in 0.1 M NaCl and 250 ug beads
were added to the RNA sample. The sample was agitated
for 20 minutes at 4°C. The beads were separated from the
RNA solution using a magnetic separation apparatus
(Promega) and the solution (containing the depleted
RNA) was removed from the beads. The depleted RNA
was ethanol precipitated and analyzed for miR-145 and
U6 snRNA expression by Northern analysis.
Transfection efficiency of the FAM-labelled 2'O-methyl
antisense miR-145 RNA oligonucleotide was conducted
in parallel with the depletion experiments. A total of 100
nM of FAM-labelled 2'O-methyl antisense miR-145 RNA
(IDT) was transfected with Lipofectamine 2000 (Invitro-
gen) into 1.2 × 105 SW620 cells expressing miR-145. At 48
hours post-transfection, the cells were harvested and sub-
jected to FACS analysis.
Northerns for miRNAs
TRIzol extraction of total RNA was carried out according
to the manufacturer's specifications (Invitrogen). Briefly,
cells were washed with PBS and 5 mL TRIzol reagent
added and cells incubated for 5 minutes at room temper-
ature. After adding 1 mL chloroform, cells were shaken
vigorously for 15 seconds by hand. The samples were cen-
trifuged and the aqueous layer transferred to a 15 mL fal-
con tube containing 2.5 mL isopropanol. The samples
were incubated at room temperature for 20 minutes, cen-
trifuged as above to pellet the RNA and resuspended with
1 mL 75% EtOH. RNA was pelleted by centrifugation, air-
dried and resuspended in 50 μL DEPC water (Ambion).
Northern analysis was conducted using 15% PAGE-Urea
gels, prepared using the SequaGel Sequencing System
(National Diagnostics), and electrophoresis was carried
out using the MiniProtean II gel electrophoresis apparatus
(BioRad). A total of 40 μg RNA was added to 10 μl RNABMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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loading dye (2× solution of 95% Formamide, 18 mM
EDTA, and 0.025% SDS, Xylene Cyanol, and Bromophe-
nol Blue) and incubated at 65°C for 10 minutes. The sam-
ples were loaded onto the 15% PAGE-Urea/TBE gel and
electrophoresed in 1× TBE at 100 V until the bromophe-
nol blue dye reached the bottom of the gel. The RNA was
transferred onto the Hybond-N+ membrane (GE Health-
care) using the Mini Trans-Blot Electrophoretic Transfer
Cell (BioRad) in 0.5× TBE buffer with 80 V for 1 hour. The
RNA was cross-linked to the membrane using the UV Stra-
talinker 1800 (1200 joules) (Stratagene).
Membranes were pre-hybridized in 10 mL Express hybrid-
ization solution (Clontech) at 37°C. The Starfire oligonu-
cleotide probe was boiled for 1 minute and then added to
the hybridization solution. After overnight hybridization
at 37°C, the hybridization solution was removed and the
membrane rinsed three times with 2× SSC/0.1% SDS and
further washed with 2× SSC/0.1% SDS solution at 37°C
for 15 minutes. The membrane was exposed to a Storage
Phosphor Screen (GE Healthcare) overnight and imaged
using the Typhoon Trio machine (GE Healthcare). The
membrane was stripped of the bound probe by pouring
boiling 0.1% SDS directly onto the membrane and then
allowing the solution to slowly cool over a 30 minute
period.
Custom Starfire oligonucleotide probes were synthesized
by Integrated DNA Technologies (IDT). The lyophilized
oligonucleotide probes were diluted to 100 μM stock
Table 1: miRNAs differentially expressed between CRC and normal colorectal tissue.
miRNA Normala CRCa p-value fold changeb Locationc CRC Fragile sited
hsa-miR-20a 9.2 10.3 2.0E-03 2.1 13q31.3 gain
hsa-miR-18a 7.6 8.6 2.9E-03 2.0 13q31.3 gain
hsa-miR-19a 7.7 8.7 2.3E-03 1.9 13q31.3 gain
hsa-miR-17-5p 10.5 11.4 1.5E-03 1.9 13q31.3 gain
hsa-miR-19b 11.0 11.8 3.4E-03 1.8 13q31.3 gain
hsa-miR-203 8.4 9.7 2.2E-02 2.6 14q32.33 loss
hsa-miR-21 13.0 14.5 6.0E-06 2.9 17q23.2 gain
hsa-miR-34a 9.5 10.3 1.5E-02 1.7 1p36.22 loss
hsa-miR-181b 8.5 9.2 2.2E-04 1.7 1q31.1 or 9q33.3 gain (1q)
hsa-miR-29b 9.7 10.5 4.9E-03 1.8 1q32.2 or 7q32.3 gain
hsa-miR-130b 7.1 7.8 1.2E-03 1.7 22q11.21 loss
hsa-miR-95 6.1 6.8 1.1E-02 1.6 4p16.1 loss
hsa-miR-106b 9.5 10.3 1.0E-04 1.7 7q22.1 gain
hsa-miR-93 9.9 10.5 3.4E-03 1.6 7q22.1 gain
hsa-miR-25 9.0 9.6 1.4E-02 1.6 7q22.1 gain
hsa-miR-182 7.2 8.7 2.8E-03 2.8 7q32.2 gain
hsa-miR-96 6.7 7.7 8.4E-03 2.0 7q32.2 gain
hsa-miR-183 5.9 6.8 2.3E-03 1.8 7q32.2 gain
hsa-miR-29a 12.1 12.9 3.6E-04 1.7 7q32.3 gain
hsa-miR-31 6.4 8.7 2.6E-03 5.0 9p21.3
hsa-miR-106a 10.7 11.7 5.1E-04 2.0 Xq26.2
hsa-miR-224 6.9 8.4 1.1E-03 2.8 Xq28
hsa-miR-30a-5p 11.6 11.0 1.6E-05 0.7 6q13 loss
hsa-miR-30a-3p 7.1 6.3 7.3E-04 0.5 6q13 loss
hsa-miR-378* 7.6 6.5 1.3E-05 0.4 5q32 loss
hsa-miR-422b 10.9 9.6 8.3E-05 0.4 5q32 loss
hsa-miR-143 14.1 12.6 1.0E-02 0.4 5q32 loss
hsa-miR-145 15.0 13.2 1.2E-03 0.3 5q32 loss
hsa-miR-10b 11.0 10.1 2.1E-02 0.5 2q31.1
hsa-miR-30c 10.9 10.3 4.0E-04 0.7 1p34.2 or 6q13 loss
hsa-miR-125a 11.2 10.2 6.4E-03 0.5 19q13.41 gain
hsa-miR-1 9.0 7.0 1.6E-03 0.2 18q12.3 or 20q13.33 loss (18q) or gain (20q)
hsa-miR-133a 10.0 7.6 6.5E-04 0.2 18q12.3 or 20q13.33 loss (18q) or gain (20q)
hsa-miR-497 9.3 8.1 9.8E-04 0.4 17p13.1 loss
hsa-miR-195 11.1 9.5 4.2E-05 0.3 17p13.1 loss
hsa-miR-422a 10.0 8.8 7.3E-05 0.4 15q22.31 loss
hsa-miR-139 7.6 6.2 1.1E-05 0.4 11q13.4 loss
a. normalized median signal intensity (log2)
b. cancer:normal
c. Chromosomal location of some miRNAs equivocal since MirVana Bioarray does not discriminate between pre-miRNA precursors.
d. Frequent chromosomal gains or lossesd in CRC as summarized from [31].BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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solution in 1× TE pH 8.0. The labelling reaction included
1× exo- reaction buffer (NEB), 1 μL Starfire Universal tem-
plate oligonucleotide (IDT) and 0.5 pmol Starfire oligo-
nucleotide probe. The reaction mix was boiled for 1
minute and then allowed to cool to room temperature for
5 minutes before adding 50 μCi α-32P-dATP (10 mCi/mL,
6000 Ci/mmol) (Perkin-Elmer) and 5 U exo-  Klenow
DNA polymerase (NEB) and incubating at room temper-
ature for 90 minutes. The reaction was stopped by the
addition of 40 μL 10 mM EDTA. The unincorporated α-
32P-dATP was removed from the reaction mix using
MicroSpin G-25 columns (GE Healthcare) according to
manufacturer's instructions. Prior to use, the probe was
boiled for 1 minute. Sequences of Starfire probes used are
shown in Additional File 3.
The U6 snRNA oligonucleotide probe (5' AAC GCT TCA
CGA ATT TGC GT 3') was end labeled using 20 pmole oli-
gonucleotide probe, 1× T4 polynucleotide buffer (NEB),
50 μCi γ-32P-dATP (10 mCi/mL, 6000 Ci/mmol) (Perkin
Elmer) and 10 U T4 polynucleotide kinase (NEB), in a
final volume of 20 μL. The probe was incubated for 30
minutes at 37°C. The reaction was stopped by the addi-
tion of 40 μL 10 mM EDTA. The unincorporated γ-32P-
dATP was removed from the reaction mix using MicroS-
pin G-25 columns (GE Healthcare) according to manufac-
turer's instructions. Prior to use, the probe was boiled for
5 minutes.
MiRNA target prediction and functional analysis
META-miR:Target Inference (MAMI - Meta prediction of
microRNA targets, http://mami.med.harvard.edu/) was
Two-way hierarchical clustering of CRC and normal colorectal tissue using 37 differentially expressed miRNAs Figure 1
Two-way hierarchical clustering of CRC and normal colorectal tissue using 37 differentially expressed miR-
NAs. The hypergeometric mean of the log2 signal intensity was calculated across all samples using a euclidean distance metric 
with complete linkage. Red and blue indicates miRNAs expressed at a high or low level relative to other samples in the dataset, 
respectively. The miR-143-145 and miR-17-92 clusters are indicated by vertical blue and red bars, respectively. Samples are 
grouped into two main clusters: Cluster I primarily represents normal colorectal tissue, and clusters II represents CRC sam-
ples. Replicate samples are indicated by the suffix "2".BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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used for miRNA target prediction. This tool performs a
meta-analysis of mRNA targets derived from all available
target prediction algorithms. Initially, a predicted target
gene set was generated by MAMI from differentially
expressed miRNAs. Sensitivity and specificity thresholds
were set in order to identify approximately 300 or more
target mRNAs. Second, gene ontology enrichment analy-
sis of biological processes (hierarchical level 5) was
applied on this set of predicted miRNA target genes, in
which the human genome was used as a reference set [30].
Gene Ontology terms or KEGG pathway enrichment was
determined by Fisher Exact test with a p value less than
0.05. In addition, enrichment analysis of signaling path-
ways, comparative analysis of biological functions and
disease categories were performed to further investigate
functional characterization of the enriched target genes
using Ingenuity Pathway Analysis (Ingenuity Systems).
Results
Profiling miRNA in clinical CRC samples
We initially profiled 64 samples from 49 patients with
colorectal cancer (4 matched adjacent normal colorectal
tissues, 4 Stage I, 19 Stage II, 20 Stage III, and 2 Stage IV
CRC; plus 15 replicates) for differential miRNA expres-
sion between normal and tumor tissues and also between
stage II and stage III disease (Additional File 1). A total of
37 differentially expressed miRNAs were identified
between clinical CRC tissues and adjacent normal color-
ectal tissue (Table 1). Most of these miRNAs are associated
with chromosomal regions that are known to have fre-
quent gains or losses in CRC [31]. Supervised hierarchical
clustering of the 37 miRNAs showed that many were co-
ordinately expressed, including the miR-143-145 and
miR-17-92 clusters, which were consistently down- or up-
regulated in CRC, respectively (Fig. 1).
Correlation of miRNA expression comparing the mirVana Bioarray and ABI Taqman platforms Figure 2
Correlation of miRNA expression comparing the mirVana Bioarray and ABI Taqman platforms. Linear regres-
sion was performed on miRNAs that were measured on both platforms. Four different CRC clinical samples were examined. 
Taqman and Ambion miRNA expression is measured in Ct and log2 units, respectively. The Pearson correlation was calculated 
for each comparison.BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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To validate the MirVana miRNA expression profiles on a
different platform we performed Taqman QPCR analysis
on 169 miRNAs in four of the clinical CRC samples (Fig.
2). The median correlation of miRNA expression between
platforms was 0.81. Hierarchical clustering also demon-
strated that replicate samples were proximal to each other,
further indicating highly reproducible results. In addition,
miRNAs could be reproducibly detected in four matched
FFPE and fresh frozen CRC samples using the ABI QPCR
platform with a median correlation of 0.81 (Fig. 3).
Reproducible detection of miRNAs in FFPE samples was
an important observation since these samples are widely
available for diagnostic testing.
In addition, we investigated whether any miRNAs were
associated with CRC progression. A set of 22 miRNAs
were found to be differentially expressed between normal
and early stage (mostly stage II) CRC including increases
in miR-21 and miR-224 and decreases in miR-133a and
miR-145 (Table 2). Six miRNAs showed significant differ-
ential expression between early and late stage (mostly
stage III) disease including an increase in miR-31 expres-
sion (Table 3). Both miR-133a and miR-378* were signif-
icantly reduced from normal tissue through stages II and
III of CRC. This indicates that loss of these miRNAs is
associated with later stage disease progression.
Profiling miRNA in CRC cell lines
To identify a CRC cell line for functional analysis of differ-
entially expressed miRNAs, and to examine the relation-
ship between miRNA expression in clinical samples and
cell lines, we compared miRNA expression between nor-
mal colonic epithelial cells and four CRC cell line models
(SW480, SW620, KM12C, KM12SM). From this analysis,
43 miRNAs were identified as either 2-fold up- or 2-fold
down-regulated in at least one of the four CRC cell lines
miRNA expression in fresh frozen versus formalin-fixed paraffin embedded CRC samples Figure 3
miRNA expression in fresh frozen versus formalin-fixed paraffin embedded CRC samples. Taqman miRNA 
expression assays were performed on 169 miRNAs from 4 matched fresh frozen and FFPE samples and Ct measurements 
were compared by linear regression. The Pearson correlation was calculated for each comparison.BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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(Table 4). To validate the cell line microarray data, we per-
formed Northern blot analyses on 14 of the 43 miRNAs in
these and an additional 4 cell lines (Fig. 4). Of those miR-
NAs that were identified in the clinical samples, only 11
were in common with the 43 deregulated in the cell line
models (Table 5). This indicated that the findings from
clinical samples are not completely reproduced in cell line
models. However, the commonly deregulated miRNAs
included miR-31, members of the miR-17-92 cluster,
miR-1, miR-143 and miR145, thereby validating the find-
ings of previous studies.
miR-143 has a tumor suppressor effect in metastatic CRC 
cells
MiR-143 and miR-145 consistently displayed reduced
expression levels in CRC clinical samples and were unde-
tectable in CRC cell line models. Over-expression of miR-
143 and miR-145 has previously been shown to result in
a tumor suppressor effect in non-metastatic CRC cell lines
[21,27,32]. In contrast, in the current study we examined
the activity of these miRNAs in the metastatic CRC context
using the SW620 cell line model (Fig. 5). Seven stable
clones expressing miR-143 were isolated and each dis-
played a cell clumping phenotype, which was associated
with increased E-cadherin protein expression (Fig. 5A-C).
No difference in cell proliferation rates was observed
(data not shown), however, reduced anchorage-inde-
pendent growth was demonstrated in all clones (Fig. 5D).
There was no correlation between the level of miR-143
expression, E-cadherin, or the degree of growth inhibi-
tion.
miR-145 has an oncogenic effect in metastatic CRC cells
A stable pooled population of SW620 cells expressing
detectable steady-state levels of mature miR-145 (desig-
nated SW620/miR-145) was generated (Fig. 6A). The level
of miR-145 approximated those observed in normal
colonic epithelial tissue as determined by U6 snRNA-nor-
malized Northern analysis (Fig. 4 and Fig. 6a). A major
distinguishing feature of the SW620/miR-145 cell popula-
tion was the change from the round single cells of SW620
to elongated cells with extended processes typical of
fibroblast-like cells (Fig. 6B). The SW620/miR-145 cells
also showed a 50% to 95% increase in cell proliferation/
metabolic activity when grown in the presence or absence
of serum, respectively (Fig. 6C). A two-fold increase in
anchorage-independent growth when grown in the pres-
ence of serum was also observed (Fig. 6C). The epithelial
cell marker E-cadherin was also reduced by 50% in
SW620/miR-145 cells compared to controls (Fig. 6D),
which is consistent with the mesenchymal-like cell mor-
phology and increased proliferation observed for SW620/
miR-145 cells.
To confirm that the changes in SW620/miR-145 cells were
due to miR-145 expression we performed miR-145-spe-
cific 2'O-methyl (2'Ome) antisense RNA knock down
experiments. MiR-145 was depleted in SW620/miR-145
cells receiving the miR-145-specific 2'Ome antisense RNA
but not in the sense control (Fig. 7A). Over-expression of
miR-145 in the presence of sense control RNA resulted in
increased cell proliferation in serum, and more markedly
in serum-free medium (Fig. 6C and 7B). However, when
antisense miR-145 RNA was transfected into SW620/miR-
145 cells there was a reversion of the high proliferative
potential of the cells (Fig. 7B). These results indicated that
it was the specific ectopic expression of miR-145 that
induced changes in cell differentiation and increased the
proliferative potential of this cell line model.
Genetic network analysis of miR-143 and miR-145 targets
The above data indicated that over-expression of miR-145
leads to an oncogenic phenotype in metastatic CRC cells,
Table 3: miRNAs differentially expressed in early (I and II) vs late 
stage (III and IV) disease.
Sample ID Stage I/II Stage III/IV Fold change p-value
hsa-miR-31 7.11 9.97 7.22 1.53E-03
hsa-miR-7 7.77 8.85 2.11 1.96E-02
hsa-miR-99b 8.74 8.12 0.65 3.64E-03
hsa-miR-378* 6.85 6.23 0.65 3.02E-02
hsa-miR-133a 7.64 6.96 0.63 1.64E-02
hsa-miR-125a 10.64 9.76 0.54 2.69E-03
Fold change = Stage III/IV:Stage I/II
Table 2: miRNAs differentially expressed between normal colon 
and early stage colorectal cancer (Stages I and II).
miRNA Normal Stage I/II Fold change p-value
hsa-miR-224 6.89 8.67 3.45 1.80E-02
hsa-miR-21 13.02 14.49 2.78 1.52E-04
hsa-miR-34a 9.48 10.43 1.92 1.92E-02
hsa-miR-106a 10.68 11.57 1.85 2.88E-02
hsa-miR-18a 7.51 8.38 1.83 3.32E-02
hsa-miR-29b 9.70 10.56 1.82 3.27E-03
hsa-miR-19b 10.84 11.69 1.80 2.77E-02
hsa-miR-106b 9.45 10.26 1.76 1.37E-02
hsa-miR-20a 9.28 10.06 1.72 3.75E-02
hsa-miR-29a 12.14 12.89 1.68 9.84E-04
hsa-miR-181b 8.41 9.11 1.63 9.47E-03
hsa-miR-19a 7.78 8.45 1.60 2.58E-02
hsa-miR-95 6.12 6.79 1.59 3.33E-02
hsa-miR-516-3p 4.87 5.52 1.57 3.20E-02
hsa-miR-378* 7.53 6.85 0.62 1.87E-03
hsa-miR-422b 10.88 10.02 0.55 4.91E-03
hsa-miR-422a 10.05 9.19 0.55 9.57E-03
hsa-miR-30a-3p 7.14 6.24 0.54 1.51E-02
hsa-miR-139 7.62 6.17 0.37 5.75E-03
hsa-miR-195 11.04 9.52 0.35 2.37E-02
hsa-miR-145 15.11 13.46 0.32 4.30E-02
hsa-miR-133a 10.51 7.64 0.14 3.00E-02
Fold change = cancer:normalBMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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the opposite effect of miR-143. We therefore performed
bioinformatic analyses to help elucidate the difference
between miR-143 and miR-145 biology. To that end we
investigated the biological pathways regulated by these
miRNAs by performing gene set enrichment analysis of
their predicted mRNA targets [33]. To validate the
approach we first examined the predicted 1683 mRNA tar-
gets of the 37 miRNAs differentially expressed between
normal colon mucosa and CRC tissue. The significant
enrichment of CRC associated pathways, including WNT/
β-catenin, TGF-β, and ERK/MAPK, indicated that this
approach was valid (Table 6). When this analysis was per-
formed specifically for miR-145 and miR-143 targets, no
significant overlap of pathways was found indicating that
the two co-expressed miRNAs target different biological
pathways, possibly explaining the opposing phenotypes
observed.
Genetic network analysis of miR-145 targets in metastatic 
versus non-metastatic cells
Previous studies have demonstrated that over-expression
of miR-145 has tumor suppressor effects in non-meta-
Table 4: MiRNAs differentially expressed in four CRC cell lines vs normal colorectal tissue.
MiRNA SW480 SW620 KM12C KM12SM Expression
hsa-let-7e 1.06 0.57 0.68 0.48 down
hsa-let-7f-1 0.46 0.41 0.40 0.36 down
hsa-let-7f-2 0.41 0.41 0.37 0.34 down
hsa-miR-1 0.33 0.51 0.56 0.29 down
hsa-miR-100 0.56 0.92 0.64 0.41 down
hsa-miR-106a 0.92 3.78 2.48 2.14 up
hsa-miR-107 0.48 1.00 1.04 1.03 down
hsa-miR-10a 2.38 0.98 0.31 0.50 up/down
hsa-miR-122a 0.82 0.57 0.59 0.43 down
hsa-miR-125a 0.53 0.43 0.26 0.30 down
hsa-miR-125b 0.12 0.37 0.07 0.16 down
hsa-miR-126 0.17 0.09 0.06 0.07 down
hsa-miR-140 2.27 1.06 1.58 1.43 up
hsa-miR-141 0.30 0.18 1.64 1.55 up/down
hsa-miR-143 0.03 0.01 0.02 0.01 down
hsa-miR-145 0.05 0.02 0.03 0.02 down
hsa-miR-150 0.34 0.32 0.38 0.24 down
hsa-miR-151-3p 0.62 0.45 0.79 0.50 down
hsa-miR-15b 2.14 1.45 1.89 1.46 up
hsa-miR-17-5p 0.76 3.05 2.31 1.80 up
hsa-miR-18a 0.55 2.22 2.16 1.79 up
hsa-miR-181a 0.47 1.49 1.27 1.38 up/down
hsa-miR-186 0.47 2.11 0.67 0.60 down
hsa-miR-188 0.72 1.27 1.37 0.46 down
hsa-miR-192 0.02 0.08 0.18 0.28 down
hsa-miR-194 0.03 0.10 0.27 0.38 down
hsa-miR-19a 0.59 2.48 1.79 1.25 up
hsa-miR-20a 0.75 3.29 1.99 1.99 up
hsa-miR-200a 0.26 0.97 1.59 1.93 up/down
hsa-miR-200b 0.44 0.97 1.64 2.20 up/down
hsa-miR-215 0.02 0.02 0.05 0.06 down
hsa-miR-22 0.46 0.15 0.28 0.21 down
hsa-miR-25 2.23 1.92 1.55 1.52 up
hsa-miR-26a 0.47 0.25 0.18 0.26 down
hsa-miR-298 2.38 1.00 1.69 1.41 up
hsa-miR-30a-3p 0.50 0.46 0.64 0.73 down
hsa-miR-30b 0.34 0.42 0.83 1.02 down
hsa-miR-31 0.31 0.20 1.92 2.77 up/down
hsa-miR-320 1.69 1.47 2.46 2.28 up
hsa-miR-7 1.58 2.77 2.45 1.83 up
hsa-miR-92 1.75 4.23 2.41 2.25 up
hsa-miR-93 2.16 2.27 2.31 2.45 up
hsa-miR-99a 1.23 0.69 0.70 0.49 down
miRNAs in bold were validated by Northern blot analysisBMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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Table 5: MiRNAs commonly deregulated in CRC clinical samples and CRC cell lines.
miRNA fold change location CRC Fragile site*
hsa-miR-20a up 13q31.3 gain
hsa-miR-19a up 13q31.3 gain
hsa-miR-17-5p up 13q31.3 gain
hsa-miR-93 up 7q22.1 gain
hsa-miR-25 up 7q22.1 gain
hsa-miR-31 up 9p21.3
hsa-miR-106a up Xq26.2
hsa-miR-143 down 5q32 loss
hsa-miR-145 down 5q32 loss
hsa-miR-125a down 19q13.41 gain
hsa-miR-1 down 18q12.3 or 20q13.33 loss (18q) or gain (20q)
* Summarized from [41-43]
Expression of 14 miRNAs in 8 CRC cell lines and normal colon total RNA Figure 4
Expression of 14 miRNAs in 8 CRC cell lines and normal colon total RNA. Northern blots were performed using U6 
snRNA as a normalization control.BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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static CRC cell lines such as SW480, HCT116 and DLD1
[21,27,32]. We hypothesized that the differential steady
state level of mRNA targets between metastatic and non-
metastatic cells might result in this observed dual function
of miR-145. We therefore investigated the expression pro-
files of miR-145 target genes in the isogenically matched
SW480 (non-metastatic) and SW620 (metastatic) cell
lines [34]. Expression levels of 12% (55/450) of the pre-
dicted miR-145 target mRNAs were found to be signifi-
cantly different between these cell lines. Gene set
enrichment analysis of these 55 genes identified 4 biolog-
ical pathways significantly altered in the metastatic setting
(Table 7). Of note, the G1/S cell cycle checkpoint (repre-
sented by MYC and CCND2) and neuregulin pathways
(represented by MYC and ADAM17) were down-regulated
in the SW620 cells. The expression of these genes may
therefore be related to the tumor suppressor effects
observed in non-metastatic cells, while their absence in
Over-expression of miR-143 in the SW620 cell line affects cell morphology and proliferation Figure 5
Over-expression of miR-143 in the SW620 cell line affects cell morphology and proliferation. (A) MiR-143 
genomic DNA was cloned under control of the U6 promoter (in pSilencer 2.1) and transfected into SW620 cells. Seven stable 
SW620 clones were identified that expressed miR-143 (A4, B3, B5, B6, C1, C5, and D2). U6 snRNA was used as a loading con-
trol. (B) The seven SW620/miR-143 clones were examined for cell morphology compared to vector control. (C) Western 
analysis of the SW620/miR-143 clones and control cells shows the steady-state levels of E-cadherin. E-cadherin ratios were cal-
culated using β-actin as a normalization control. (D) Seven SW620/miR-143 clones were assayed for proliferation/metabolic 
activity compared with vector control when grown in the absence (open bars) or presence of serum (solid bars). (E) The same 
clones were examined for anchorage-independent cell growth in the rapid soft agar assay in the presence of serum. Two inde-
pendent experiments were performed. ** p < 0.01, *** p < 0.001.BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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SW620 cells may cause miR-145 to act on other, yet to be
determined, anti-proliferative signaling targets.
Discussion
The expression of 37 miRNAs were found to be altered in
CRC clinical specimens compared with normal colon and
11 of these miRNAs showed the same pattern of expres-
sion in CRC cell line models. This indicated that CRC cell
lines do retain some of the miRNA expression patterns
observed in primary tumors and can act as suitable mod-
els for functional analyses of specific miRNAs. Our obser-
vation that miR-143 and miR-145 were down-regulated in
CRC confirmed earlier reports [21-25]. However, surpris-
ingly these were not found in a recent study that included
a large cohort of CRC clinical specimens [26]. Such dis-
crepancies may be explained by differences in the miRNA-
Over-expression of miR-145 in SW620 cell line affects cell morphology and proliferation Figure 6
Over-expression of miR-145 in SW620 cell line affects cell morphology and proliferation. (A) The genomic region 
surrounding the miR-145 gene was PCR-amplified and cloned into pSilencer 4.1 under control of the CMV promoter. Mature 
miR-145 was detected by Northern analysis in a pooled population of SW620 cells following transfection. U6 snRNA was used 
as a loading control. (B) A major distinguishing feature of the cell population over-expressing miR-145 was the change in cell 
morphology from the round single cells of SW620 to elongated cells with extended processes typical of fibroblast-like cells. (C) 
The miR-145-expressing SW620 cell population showed a two-fold increase in anchorage-independent growth when grown in 
the presence of serum and a greater than 50% increase in cell proliferation/metabolic activity when grown in the presence 
(solid bars) or absence (open bars) of serum. *** p < 0.001. (D) Western analysis of the SW620/miR-145 cells and control cells 
shows the steady-state levels of E-cadherin were 50% lower in SW620 cells expressing the mature miR-145. FBS = fetal bovine 
serum, SF = serum-free.BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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detection platforms used or clinical sample characteris-
tics. We also verified the previously reported down-regu-
lation of miR-30a-3p [22], miR-10b, miR-30c, miR-125a,
miR-1, miR-133a, and miR-195 [35].
MiR-31, miR-21 and members of the miR-17-92 cluster,
and its paralogues, were shown to be up-regulated in CRC.
The increase in miR-31 was reported previously [22], but
was not found in several other miRNA expression studies
in CRC [23,26,27,35,36]. A total of 22 miRNAs were
deregulated in the early stages of CRC. These miRNAs
such as miR-224 and miR-21 should be further examined
for their utility as diagnostic biomarkers of CRC. For
example, such biomarkers could be assayed for individu-
als at high risk of CRC in non-invasive tissues such as
blood or stool. Indeed the utility of miR-21 as a diagnos-
tic, prognostic, and a marker of therapeutic response has
been confirmed in other studies [23,26,27,35,36]. The 6
miRNAs that displayed different expression levels
between early (mostly stage II) and late stage (mostly
stage III) samples should also be analyzed for their associ-
ation with clinical outcome. For instance gene expression
profiles have been used to predict prognosis of stage II
CRC patients with the goal of upgrading these individuals
to chemotherapy regimens in addition to the standard of
care surgery [37]. Interestingly, the recent work by Schetter
and colleagues did not identify any of these 6 miRNAs as
potential prognostic markers since they only focused on
miRNAs that were differentially expressed between nor-
mal and all CRC stages. Addressing these questions will
require the examination of large sets of clinically relevant
biospecimens. To this end, we also demonstrated repro-
ducible detection of miRNA in clinically relevant FFPE
CRC samples, indicating that miRNAs are stable in this
poorly preserved material [38].
We found that miR-143 re-expression in SW620 cells con-
verted the round, independent cells into aggregated cell
masses, increased E-cadherin expression and decreased
cell proliferation/metabolism, all consistent with a transi-
tion to a more epithelial-like cell phenotype. Akao and
colleagues have also demonstrated a reduction in cell via-
bility upon delivery of pre-miR-143 into the non-meta-
static DLD1 or SW480 CRC cell lines, which is consistent
with our observations [21]. However, in contrast to our
findings, the previous reports demonstrated dose-depend-
ent tumor-suppressor effects of miR-143. These conflict-
ing data may be due to the different cell lines models used
and/or the methods used for expressing miR-143. For
instance, we generated stable clones while previous stud-
ies performed transient transfections with synthetic pre-
miR-143. These factors may affect the mechanisms by
which the targeted pathways are regulated.
In contrast to the miR-143 tumor suppressor effects,
replacing miR-145 activity in the same cells led to an elon-
gated cell phenotype, increased E-cadherin, and increased
cell proliferation/metabolism (all consistent with a mes-
enchymal-like phenotype). The epithelial-mesenchymal
transition (EMT) represents a critical component of the
progression of carcinomas towards invasive and meta-
static disease, as well as allowing epithelial cells to escape
the constraints of the tissue architecture. In CRC it has
been reported that EMT enhances the migratory ability of
cells, leads to acquisition of autocrine growth factor sign-
aling loops, increased expression of relevant integrins and
mechanism to evade apoptosis [39]. Therefore miR-145
may be an activator of the transition to a more mesenchy-
mal-like phenotype thus advancing tumor evolution,
whereas miR-143 may contribute as a guardian of the epi-
thelial-like state (both consistent with their opposing
impacts on the metastatic cell model SW620).
Antisense-mediated reversion of miR-145-induced prolifera- tion Figure 7
Antisense-mediated reversion of miR-145-induced 
proliferation. (A) Total RNA from treated samples showed 
that miR-145 was depleted in cells receiving the miR-145-
specific 2'Ome antisense RNA but not in the mock treated, 
or miR-145 sense treated controls. (B) As expected, SW620/
miR-145 expressing pools showed increased proliferation 
compared to vector controls in the presence (solid bars) or 
absence (open bars) of serum. When treated with miR-145 
antisense RNA, a reduction in proliferation was seen in both 
SW620/vector and SW620/miR-145 pools. Three independ-
ent experiments were performed. * p < 0.05; ** p < 0.01, *** 
p < 0.001.BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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Table 6: Pathways targeted by CRC miRNAs
p-value
Pathway miRNA targets enriched Known colon cancer genes
B Cell Receptor Signaling 3.02E-08 3.16E-07
IL-6 Signaling 4.27E-07 1.38E-04
Glucocorticoid Receptor Signaling 7.41E-07 6.17E-10
ERK/MAPK Signaling 1.51E-06 2.51E-03
Ephrin Receptor Signaling 4.90E-06 5.62E-04
Ceramide Signaling 1.02E-05 8.32E-07
TGF-beta Signaling 2.63E-05 2.04E-06
Neurotrophin/TRK Signaling 3.02E-05 1.35E-04
Axonal Guidance Signaling 5.01E-05 6.17E-06
SAPK/JNK Signaling 5.37E-05 2.24E-02
Wnt/beta-catenin Signaling 6.03E-05 1.58E-08
Hypoxia Signaling in the Cardiovascular System 6.61E-05 3.55E-02
T Cell Receptor Signaling 8.51E-05 2.69E-02
p38 MAPK Signaling 9.77E-05 1.20E-03
Acute Phase Response Signaling 2.34E-04 4.37E-07
Hepatic Fibrosis/Hepatic Stellate Cell Activation 3.89E-04 2.51E-15
FGF Signaling 4.57E-04 9.33E-08
EGF Signaling 7.76E-04 1.29E-04
PPAR Signaling 8.91E-04 5.37E-03
PDGF Signaling 1.00E-03 6.03E-05
PPARalpha/RXRalpha Activation 1.23E-03 4.90E-04
PI3K/AKT Signaling 1.62E-03 1.62E-08
Cell Cycle: G1/S Checkpoint Regulation 2.24E-03 2.57E-04
Hepatic Cholestasis 2.24E-03 6.92E-03
IGF-1 Signaling 2.88E-03 3.31E-05
Huntington's Disease Signaling 5.13E-03 1.45E-07
Integrin Signaling 5.13E-03 5.37E-04
Apoptosis Signaling 5.62E-03 1.26E-11
Death Receptor Signaling 6.17E-03 2.82E-09
Insulin Receptor Signaling 7.08E-03 5.25E-05
Fc Epsilon RI Signaling 7.24E-03 1.38E-09
PTEN Signaling 7.59E-03 1.86E-10
IL-10 Signaling 7.94E-03 1.74E-02
Actin Cytoskeleton Signaling 1.41E-02 9.77E-03
Synaptic Long Term Depression 1.95E-02 2.57E-02
JAK/Stat Signaling 2.24E-02 6.17E-05
NF-kB Signaling 2.24E-02 2.24E-05
GM-CSF Signaling 2.45E-02 5.01E-08
IL-2 Signaling 2.57E-02 1.41E-05
Chemokine Signaling 3.02E-02 5.37E-03
VEGF Signaling 3.02E-02 1.38E-07
Xenobiotic Metabolism Signaling 4.37E-02 1.78E-02
Table 7: miR-145 targeted pathways differentially expressed between SW480 and SW620 cell lines.
Pathway Genes (SW620/SW480)
Axonal guidance signaling ADAM17*, ARPC5, ADAM19, EFNA3*, PLXND1
Cell Cycle: G1/S checkpoint MYC*, CCND2*
ERK/MAPK signaling MYC*, ATF1, ETS2
Neureguin signaling MYC*, ADAM17*
* Denotes genes that are down-regulated in SW620 compared to SW480BMC Cancer 2009, 9:374 http://www.biomedcentral.com/1471-2407/9/374
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The oncogenic effects of miR-145 were enhanced when
cells were grown in serum-free medium suggesting that
cell growth factors may affect the activity of miR-145 and/
or modify the endogenous activity of pathways targeted
by this miRNA. Indeed previous reports have shown that
miR-145 leads to a tumor suppressor effect in non-meta-
static CRC cell lines (DLD1, HCT116, SW480, LS174T)
[21,27]. However, we have shown here that the steady
state level of miR-145 targets is significantly altered
between metastatic and non-metastatic cells. Moreover,
the G1/S cell cycle checkpoint (represented by MYC and
CCND2) and neuregulin (represented by MYC  and
ADAM17) pathways that are targeted by miR-145, were
found to be significantly under-expressed in the meta-
static setting. Other deregulated miR-145 targeted path-
ways included axonal guidance signaling and the ERK/
MAPK pathways. The presence and absence of these path-
ways in the non-metastatic and metastatic cells may
account for the dual tumor suppressor and oncogenic
effects of miR-145, respectively. Members of the miR-17-
92 cluster have also been shown to have either oncogenic
or tumor suppressor activity depending on the cellular
context in which they are expressed [40]. We have now
established that miR-145 can also act in this dual manner.
It should be noted however, that our results were limited
to one metastatic CRC model. To further validate our find-
ings additional metastatic models should be investigated
for a similar phenotypic impact. Nevertheless, investiga-
tors contemplating the use of miR-145 as a therapeutic
strategy for CRC should keep in mind that specific miR-
NAs may have opposing biological functions at different
stages of tumor development.
Conclusion
In summary we have screened a large set of clinical CRC
samples and matched normal colorectal tissue for miRNA
expression. Thirty seven miRNAs were found to be differ-
entially expressed between normal, early, or late stage
CRC and the deregulation of 11 of these miRNAs was con-
firmed in a panel of CRC cell line models. Larger studies
will need to be performed to test the utility of these miR-
NAs as diagnostic and prognostic markers in CRC. We elu-
cidated the opposing phenotypic effects of miR-143 and
miR-145 in metastatic CRC cells. Bioinformatic analysis
provided insight into the biological pathways controlled
by miR-143 and miR-145 and comparison of gene expres-
sion profiles has indicated that miR-145 targets are differ-
entially expressed between metastatic and non-metastatic
isogenic cell line models. Pathway analysis of these differ-
entially expressed genes identified the G1/S cell cycle
checkpoint and neuregulin pathways as being signifi-
cantly down-regulated in SW620 compared to SW480
cells thus providing an explanation as to why miR-145 has
oncogenic effects in the metastatic context in contrast to
tumor suppressor effects in the non-metastatic setting.
Importantly, our results highlight that delivery of miR-
143, in isolation, may be a potential therapeutic modality
for CRC, and that a strategy involving over-expression of
miR-145 alone should be approached with caution.
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